首页> 美国卫生研究院文献>Iranian Journal of Pharmaceutical Research : IJPR >Effect of Quaternary Ammonium Carboxymethylchitosan on Release Rate In-vitro of Aspirin Sustained-release Matrix Tablets
【2h】

Effect of Quaternary Ammonium Carboxymethylchitosan on Release Rate In-vitro of Aspirin Sustained-release Matrix Tablets

机译:季铵羧甲基壳聚糖对阿司匹林缓释基质片的体外释放速率的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of this study was to develop a derivative of chitosan as pharmaceutical excipient used in sustained-release matrix tablets of poorly soluble drugs. A water-soluble quaternary ammonium carboxymethylchitosan was synthesized by a two-step reaction with carboxymethylchitosan (CMCTS), decylalkyl dimethyl ammonium and epichlorohydrin. The elemental analysis showed that the target product with 10.27% of the maximum grafting degree was obtained. To assess the preliminary safety of this biopolymer, cell toxicity assay was employed. In order to further investigate quaternary ammonium carboxymethylchitosan application as pharmaceutical excipient, aspirin was chosen as model drug. The effect of quaternary ammonium CMCTS on aspirin release rate from sustained-release matrix tablets was examined by in-vitro dissolution experiments. The results showed that this biopolymer had a great potential in increasing the dissolution of poorly soluble drug. With the addition of CMCTS-CEDA, the final cumulative release rate of drug rose up to 90%. After 12 h, at the grade of 10, 20 and 50 cps, the drug release rate increased from 58.1 to 90.7%, from 64.1 to 93.9%, from 69.3 to 96.1%, respectively. At the same time, aspirin release rate from sustainedrelease model was found to be related to the amount of quaternary ammonium CMCTS employed. With the increase of CMCTS-CEDA content, the accumulated release rate increased from 69.1% to 86.7%. The mechanism of aspirin release from sustained-release matrix tablets was also preliminary studied to be Fick diffusion. These data demonstrated that the chitosan derivative has positive effect on drug release from sustained-release matrix tablets.
机译:这项研究的目的是开发壳聚糖衍生物作为难溶性药物缓释基质片剂中使用的药用赋形剂。通过与羧甲基壳聚糖(CMCTS),癸基烷基二甲基铵和表氯醇的两步反应,合成了水溶性羧甲基壳聚糖季铵盐。元素分析表明,获得了最大接枝度的10.27%的目标产物。为了评估这种生物聚合物的初步安全性,采用了细胞毒性试验。为了进一步研究羧甲基壳聚糖季铵盐作为药物赋形剂的应用,选择阿司匹林作为模型药物。通过体外溶出实验检查了季铵盐CMCTS对阿司匹林从缓释基质片剂中释放速率的影响。结果表明,这种生物聚合物具有增加难溶性药物溶解的巨大潜力。加入CMCTS-CEDA后,药物的最终累积释放率上升至90%。 12 h后,在10、20和50 cps的等级下,药物释放率分别从58.1增至90.7%,从64.1增至93.9%,从69.3增至96.1%。同时,从持续释放模型中发现阿司匹林释放速率与所用季铵CMCTS的数量有关。随着CMCTS-CEDA含量的增加,累积释放率从69.1%增加到86.7%。还初步研究了阿司匹林从缓释基质片剂中释放的机制为Fick扩散。这些数据表明壳聚糖衍生物对药物从缓释基质片剂的释放具有积极作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号